JPMorgan analyst Anupam Rama reiterated an Overweight rating and $191 price target on Neurocrine (NBIX) following the company’s presentation at the 2025 JPMorgan Healthcare Conference. There were no major surprises in the presentation, highlighting recent Crenessity approval, though there was an increased focus on the breadth of the pipeline, the analyst tells investors in a research note. The firm added that, on the R&D side, the company noted one new medicine reaching the market every two years.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Trump Trade: New administration to invest $20B to build data centers
- Neurocrine price target raised to $162 from $142 at UBS
- Neurocrine price target raised to $159 from $136 at RBC Capital
- Neurocrine price target raised to $165 from $160 at Barclays
- Neurocrine price target raised to $182 from $172 at BofA